Prevalence of Psoriatic Arthritis, Spondyloarthritis and Rheumatoid Arthritis in Norway Save
Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA). This has implications on diagnosis and population care. A recent analysis of Norway registry data answers this question.
Data taken from the Norwegian Patient Registry identified adult PsA, axSpA and RA patients to calculate the point prevalence and assess the use of disease-modifying antirheumatic drugs (DMARD).
The point prevalence in Norway was:
- PsA 0.46% (higher in women than men - 0.50% vs 0.43%)
- axSpA 0.41% (higher in men than women - 0.45% vs 0.37%)
- RA 0.78% (higher in women than men - 1.10% vs 0.46%)
Biologic use in 2017 was roughly equivalent: 27.3% of RA patients, 25.7% of PsA patients and 35.1% of axSpA patients used biologic DMARDs. Biologics were more frequent in younger patients and was commonly used especially after age ≥55 years.
Combined PsA and SpA are more common than RA iIn Norway. The overall combined population prevalence of PsA, axSpA, and RA was over 1.5%.